#BEGIN_DRUGCARD DB06811

# AHFS_Codes:
Not Available

# ATC_Codes:
C05BB02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Asclera

# CAS_Registry_Number:
9002-92-0

# ChEBI_ID:
46859

# Chemical_Formula:
C14H30O2

# Chemical_IUPAC_Name:
2-(dodecyloxy)ethan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-14 10:21:11 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity.

# Dosage_Forms:
Injection	Intravenous
Injection	Intravenous

# Drug_Category:
Sclerosing Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
21414067	Weiss RA, Voigts R, Howell DJ: Absence of Concentration Congruity in Six Compounded Polidocanol Samples Obtained for Leg Sclerotherapy. Dermatol Surg. 2011 Mar 17. doi: 10.1111/j.1524-4725.2011.01906.x.
22620717	Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, Guiha I: Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012 Aug;38(8):1322-30. doi: 10.1111/j.1524-4725.2012.02422.x. Epub 2012 May 23.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.94

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
miscible

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Polidocanol

# HET_ID:
Not Available

# Half_Life:
~1.5 h.

# InChI_Identifier:
InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3

# InChI_Key:
InChIKey=SFNALCNOMXIBKG-UHFFFAOYSA-N

# Indication:
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01993

# LIMS_Drug_ID:
6817

# Mechanism_Of_Action:
When administered, Polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.

# Melting_Point:
33-36 °C

# Molecular_Weight_Avg:
230.3868

# Molecular_Weight_Mono:
230.224580204

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/info/v1us/asclera

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Polidocanol has a concentration and volume dependent damaging effect on the blood vessel endothelium.

# Predicted_LogP_Hydrophobicity:
5.15

# Predicted_LogS:
-5.1

# Predicted_Water_Solubility:
1.86e-03 g/l

# Primary_Accession_No:
DB06811

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/asclera-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCCCCCOCCO

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Dodecylpolyethyleneglycolether
Hydroxyl polyethoxy dodecane
Laureth 9
Lauromacrogol
Macrogol lauryl ether
Oxypolyethoxydodecane
PEG-9 lauryl alcohol
POE-9 lauryl alcohol
Polydocanol

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-04-26 20:50:54 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Polidocanol

# pKa_Isoelectric_Point:
Not Available

#END_DRUGCARD DB06811
